In the present study, DCIS could be detected at 63% sensitivity and early invasive breast cancer at 51% sensitivity in the test cohort using SPAG6 and ITIH5. Sensitivity for DCIS could be increased to 70% by adding PER1 and NKX2-6 to the panel. The gene discussed is PER1; the disease is ductal breast carcinoma in situ.